EN DE
Watch OraSure Technologies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OraSure Technologies Inc (OSUR) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of OraSure Technologies Inc stock $2.89, price $3.44, that is 16.0% below the price, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

OT OraSure Technologies Inc logo Thin data Nov 8, 2026

OraSure Technologies Inc

OSUR · US
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Quality 49/100
Insiders bought $224,750 (6M)
Fair value $2.89 · Overvalued (−16.0%)
Weak Growth (revenue 5y −7.7 %/yr in USD)
Loss-making · -43.7% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 14/100
Thin data
Watch OraSure Technologies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.38 $2.11 Fair Value $2.89 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $2.11 – $13.38 · fair‑value band $1.91 – $3.62 · the $3.44 price screens above the $2.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow OraSure Technologies in your weekly email

Every Wednesday you see whether OraSure Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.

Show moreShow less

It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test.

The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device.

In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.

Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae.

It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets.

The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Stock analysis

OraSure Technologies Inc (OSUR) currently trades at $3.44, while our model-based Fair Value estimate is $2.89, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.91 (bear) to $3.62 (bull), the price of $3.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

OraSure Technologies Inc reported revenue of $115M in FY2025 versus $234M in FY2021, a compound −16.2%/yr. Reported net income was −$68.7M in FY2025.

Key figures

Market cap $241M Micro · P/S ratio 2.55 · EPS (TTM) $−0.6900 · Net margin −43.7% · Return on equity −14.1% · Return on assets (EBIT) −2.7% (5-year average) · Operating margin −56.0% · Revenue (TTM) $112M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).

What moves the price

The share trades about 24% below its 52-week high and 63% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −16%, OSUR screens cheaper than that median.

Fair Value models

Bear $1.91 Fair Value $2.89 Bull $3.62
Price $3.44 · Downside -16.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.91 $2.89 $3.62 54
All 1 models by family
Asset-Based
NCAV (Graham) $1.91 $2.89 $3.62 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 56
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 63
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $224,750, on May 14, 2026.

  • BuySteven Kyle BoydDirector75,000 shares at $3.00$224,750May 14, 2026
  • BuyManner Carrie EglintonPresident & CEO, Director2× since Mar 13, 2026: 54,322 shares, avg. $2.96$160,705Mar 20, 202610b5-1 plan
  • BuyKenneth J McGrathChief Financial Officer2× since Mar 13, 2026: 54,321 shares, avg. $2.96$160,702Mar 20, 202610b5-1 plan
  • BuyNancy J GaglianoDirector2,100 shares at $2.37$4,977Nov 28, 2025

Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−38.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Start year 2020 (pandemic). Over 10 years: −0.4% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.4% (2020) → −59.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OSUR screens overvalued: fair value 16% below the price. Compare with Intuitive Surgical, Inc →

Compare OraSure Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −16.0% · Below median
Profitability
Return on assets −17.1% · Bottom 25%
Net margin (12 months) −43.7% · Bottom 25%
Operating margin (12 months) −56.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.9% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.71× · Cheapest 25%
P/S (12 months) 2.14× · Cheaper than median
PEG 6.19× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 31
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.06 +45% vs OSUR
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs OSUR
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs OSUR
Medline Inc MDLN $39.64 $28.59 −28% vs OSUR
Alcon Inc ALC CHF 61.30 CHF 33.91 −45% vs OSUR
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs OSUR
Becton, Dickinson and Company BDX $211.88 $82.34 −61% vs OSUR
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs OSUR
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs OSUR
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs OSUR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OraSure Technologies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OraSure Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/OSUR

Frequently asked questions

Is OraSure Technologies Inc (OSUR) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.89 versus a price of $3.44, about 16% lower (overvalued).
What is the fair value of OSUR?
Our model-based fair value for OraSure Technologies Inc is $2.89 (as of Nov 8, 2026), built from audited fundamentals. The current price: $3.44.
What is the quality score of OSUR?
OraSure Technologies Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OraSure Technologies Inc (OSUR)?
Our model-based price target is the fair value of $2.89 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.91, optimistic scenario $3.62. It is a calculation from audited fundamentals, not an analyst target.
What is the OraSure Technologies Inc stock forecast for 2026?
Our models put fair value at $2.89, about 16% lower versus a price of $3.44 (overvalued). Cautious scenario $1.91, optimistic scenario $3.62. The calculation is refreshed regularly with new filings.
What is the revenue of OraSure Technologies Inc (OSUR)?
OraSure Technologies Inc reported trailing-twelve-month revenue of about $112M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of OraSure Technologies Inc (OSUR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OraSure Technologies Inc it is $2.89 per share (as of Nov 8, 2026), against a price of $3.44. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is OraSure Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, OSUR trades above its calculated fair value: price $3.44, fair value $2.89, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OSUR?
No. The price is what the market pays today ($3.44); the fair value is what the company's own numbers justify ($2.89). For OraSure Technologies Inc the two are $0.5500 per share apart. That gap is exactly why we show both numbers side by side.
How much is OraSure Technologies Inc worth?
The market values OraSure Technologies Inc at about $241M (market capitalisation, as of Nov 8, 2026). Per share that is $3.44; our models calculate a fair value of $2.89 per share.
What do the bullish and bearish scenarios say about OSUR?
Our models span a range for OraSure Technologies Inc: cautious scenario $1.91, base $2.89, optimistic $3.62 per share (as of Nov 8, 2026, price $3.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of OSUR?
The PEG ratio of OraSure Technologies Inc is 6.19 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of OraSure Technologies Inc (OSUR)?
Balance-sheet figures for OraSure Technologies Inc (as of Nov 8, 2026): return on equity −14.1%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is OSUR from its 52-week high?
OraSure Technologies Inc trades at $3.44, about 24% below its 52-week high of $4.50 and 63% above the low of $2.11 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.89 is for.
Which stocks are comparable to OraSure Technologies Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OraSure Technologies Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $3.44, calculated fair value $2.89 (−16%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OSUR calculated?
We run OraSure Technologies Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $2.89 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. OraSure Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OraSure Technologies Inc (OSUR)?
The closing price on Nov 6, 2026 was $3.44. Our model-based fair value is $2.89, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OraSure Technologies Inc right now?
Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($1.91 to $3.62) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of OraSure Technologies Inc

How large is the market capitalisation of OraSure Technologies Inc (OSUR)?
The market capitalisation of OraSure Technologies Inc is $241M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OraSure Technologies Inc (OSUR)?
The price-to-sales ratio of OraSure Technologies Inc is 2.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OraSure Technologies Inc (OSUR)?
Earnings per share at OraSure Technologies Inc are $−0.6900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of OraSure Technologies Inc (OSUR)?
The net margin of OraSure Technologies Inc is −43.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OraSure Technologies Inc (OSUR)?
The return on equity (ROE) of OraSure Technologies Inc is −14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OraSure Technologies Inc (OSUR)?
On an EBIT basis the return on assets of OraSure Technologies Inc is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OraSure Technologies Inc (OSUR)?
The operating margin of OraSure Technologies Inc is −56.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OraSure Technologies Inc (OSUR)?
Revenue at OraSure Technologies Inc is growing −1.9% versus a year earlier (3y avg −33.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OraSure Technologies Inc (OSUR)?
Earnings per share at OraSure Technologies Inc are growing +29.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does OraSure Technologies Inc (OSUR) generate?
The free cash flow of OraSure Technologies Inc is −$53.2K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OraSure Technologies Inc (OSUR) hold?
OraSure Technologies Inc holds more cash than debt, $186M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch OraSure Technologies Inc in the live analysis

One click puts OraSure Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.